|Year : 2015 | Volume
| Issue : 4 | Page : 148-153
Effect of Brahmyadi Churna (Brahmi, Shankhapushpi, Jatamansi, Jyotishmati, Vacha, Ashwagandha) and tablet Shilajatu in essential hypertension: An observational study
Arshiya Ali1, Dilshad Umar2, Mohammed Farhan3, Bahija Basheer2, Kusai Baroudi2
1 Department of General Medicine, Alvas Ayurvedic College and Hospital, Moodbidri, Karnataka, India
2 Department of Preventive Dental Sciences, Al Farabi Colleges, Riyadh, Saudi Arabia
3 Department of Pedodontics, Century Dental College, Kasargod, Kerala, India
|Date of Web Publication||5-Oct-2015|
Department of Preventive Dental Sciences, Al Farabi Colleges, Riyadh
Source of Support: None, Conflict of Interest: None
Hypertension (HTN) is one among the fiery health problems of the present era. Since it does not cause symptoms usually for many years until a vital organ is damaged. The present study was carried out on 40 patients of essential HTN with Brahmyadi Churna and tablet Shilajatu for a period of 1 month with milk as Anupana. Observation was done before the treatment, 3 mid test assessments on 7 th , 14 th , and 21 st day, posttest assessment was done on 30 th day. Intervention revealed that 19 had marked improvement, 14 had moderate improvement, 5 had mild improvement, and no improvement was noticed in 2 individuals. Reduction in blood pressure was observed markedly with P < 0.000.
Keywords: Brahmyadi Churna, essential hypertension, postural changes
|How to cite this article:|
Ali A, Umar D, Farhan M, Basheer B, Baroudi K. Effect of Brahmyadi Churna (Brahmi, Shankhapushpi, Jatamansi, Jyotishmati, Vacha, Ashwagandha) and tablet Shilajatu in essential hypertension: An observational study. J Adv Pharm Technol Res 2015;6:148-53
|How to cite this URL:|
Ali A, Umar D, Farhan M, Basheer B, Baroudi K. Effect of Brahmyadi Churna (Brahmi, Shankhapushpi, Jatamansi, Jyotishmati, Vacha, Ashwagandha) and tablet Shilajatu in essential hypertension: An observational study. J Adv Pharm Technol Res [serial online] 2015 [cited 2022 May 22];6:148-53. Available from: https://www.japtr.org/text.asp?2015/6/4/148/165015
| Introduction|| |
Hypertension (HTN) being a chronic illness constitutes an important public health challenge because of its prevalence and concomitant increase in the risk of cardiovascular diseases. In India, 14% of people suffer from HTN  and majority of them have essential HTN. It is estimated that 1 billion people are affected worldwide.  As most of the patients suffering from abnormally elevated blood pressure (BP) are asymptomatic, diagnosis is either missed or delayed. HTN remains one of the most frequent risk factors for cardiovascular/cerebrovascular morbidity and mortality. 
Modern style of living might have given man all comforts that he has craven for, but in the meantime it has a darker side too, and one of them is the increase in the incidence of lifestyle disorders, to mention few are obesity, diabetes, and HTN. 
HTN is classified as either primary (essential) HTN or secondary HTN, about 90-95% of cases are categorized as "primary HTN" which means high BP (HBP) with no obvious underlying medical cause.  The remaining 5-10% of cases (secondary HTN) are caused by other conditions that affect the other system such as kidneys, arteries, heart, or endocrine system.
Though direct references regarding HTN are not available in the classical literature of Ayurveda, attempts are made to explain HTN according to the Dosha and Dhatu involvement. The lifelong and palliative treatment of HTN in western medicine induces many side effects. Therefore, to attain and to maintain good health, hypertensive patients are looking toward Ayurveda. In this study, an attempt is made to probe the possibility of managing HTN with drugs which have lesser side effects, especially considering the chronicity and lifelong nature of the disease.
Aim and objective
To evaluate the combined effect of Brahmyadi Churna (Brahmi, Shankhapushpi, Jyotishmati, Jatamansi, Vacha, Ashwagandha 1 Part each) and tablet Shilajatu in the management of essential HTN.
| Material and methods|| |
- Brahmyadi Churna (Brahmi, Shankhapushpi, Jatamansi, Jyotishmati, Vacha, Ashwagandha Churna 1 part each)
- Shilajatu Vati.
The ingredients of Brahmyadi compound were procured from Abdul Ravoof and son's Pansari Shop, Mysore. It was made into powder, mixed well in a container and used.
Shilajatu Vati was procured from SDP Pharmacy, Puttur.
The identification of the individual raw drugs was done by experts in the field.
Source of data
Patients of either sex diagnosed to be suffering from essential HTN were selected from the OPD, IPD of Alvas Ayurveda Medical College, Moodbidri.
Totally, 40 cases of essential HTN were selected incidentally. The patients were registered for the present study with the help of proforma prepared for the study.
The 7 th Report of the Joint National committee on prevention, detection, evaluation, and intervention of HBP were considered as the standard for the diagnosis of HTN. 
Headache, palpitation, chest pain, insomnia, fatigue, and giddiness.
- Patients of either sex between the age group of 30-70 years either treated or freshly detected cases of essential HTN were selected
- Patient with pre-HTN and HTN stage 1 with or without symptoms were included for the study.
Patients suffering from any other systemic disorders which interfere with the course of the disease and intervention were excluded.
Descriptive statistics, Chi-square test, contingency coefficient analysis, repeated measure ANOVA, paired samples t-test using SPSS program version 20.0 (Illinois, USA).
Patients were subjected for routine investigations of blood, urine, etc., to exclude any other systemic disorders.
· Brahmyadi Churna 6 g tid after food with milk
(Dried Panchanga of Brahmi and Shankhapushpi, Roots of Jatamansi and Ashwagandha, seeds of Jyotishmati, stem of Vacha, 1 part each were taken and made into Churna [powder form] and mixed well in a container)
· Tablet Shilajatu 1 bid after food with milk
Duration: 30 days
Patients were advised for limiting the usage of salt, restricting the intake of fat rich food, quitting smoking and alcohol, and managing stress levels.
The assessment was done considering systolic BP (SBP), diastolic BP (DBP), and mean BP readings in all the three postures that is, supine, sitting, and standing at pretest that is, 0 th day, 3 mid test assessments on 7 th , 14 th , 21 st day, respectively and posttest on 30 th day [Table A].
The overall assessment of the intervention was interpreted as reduction in SBP and DBP in the range of:
- Marked improvement - SBP 30-40 mm of Hg and DBP up to ≤15 mm of Hg
- Moderate improvement - SBP 20-29 mm of Hg and DBP 11-14 mm of Hg
- Mild improvement - SBP 10-19 mm of Hg and DBP 5-10 mm of Hg
- No improvement - Reduction in SBP in the range of 0-9 mm of Hg and DBP in the range 0-4 mm of Hg.
The mean of both is taken and overall assessment is done.
| Observation and results|| |
Out of 40 patients, 19 fresh patients and 21 treated cases were noted. Fresh cases were observed with frequent measurement of BP and then intervention was started, in treated cases the earlier medication was withdrawn gradually and completely, after complete withdrawal of earlier treatment a flush out period of 7 days was allowed before the intervention was started. Out of 40 patients, 32 patients were symptomatic and majority of them that is, 19 patients (47.5%) had headache, followed by symptoms like insomnia in 17 patients (42.5%), fatigue 17 patients (42.5%). Fifteen patients (37.5%) with giddiness, palpitation was found in 9 patients (22.5%), and 2 patients (5%) had chest pain. Epistaxis was observed only in 2 patients (5%).
In the present study, familial predisposition was observed in 42% of the cases, excessive salt intake was observed in 50% of cases and the risk factors like smoking, obesity, alcohol was found only in 17% of cases.
On 7 th day
In the majority of patients, no much difference in BP was recorded in all the three postures. Though linear reduction in BP was observed in few cases, few cases showed a slight increase in BP when compared to previous reading.
14 th day
Reduction in SBP to an average of 15 mm of Hg and DBP to an average of 10 mm of Hg was noted. Symptoms such as headache, giddiness reduced in few patients.
21 st day
Reduction in SBP to an average of 20 mm of Hg and DBP to an average of 12 mm of Hg was observed. There was an improvement in the quality of sleep in individuals who complained of insomnia.
After the intervention, there was a significant reduction in symptoms such as giddiness, headache, fatigue, insomnia though no much improvement in palpitation, and chest pain was observed.
Overall assessment of the intervention revealed that out of 40 patients, 19 (47.5%) had marked improvement, 14 (35%) had moderate improvement, 5 (12.5%) had mild improvement, and no improvement was noticed in 2 (5%) individuals. Overall, the study revealed that the selected drugs have a significant role to play in the management of Essential HTN. Reduction in BP was observed markedly with P value 0.000 [Table 1],[Table 2],[Table 3],[Table 4],[Table 5],[Table 6],[Table 7] and [Table 8] and [Figure 1],[Figure 2],[Figure 3],[Figure 4],[Figure 5],[Figure 6],[Figure 7],[Figure 8] and [Figure 9].
|Figure 1: Descriptive statistics of systolic blood pressure in supine posture|
Click here to view
|Figure 2: Descriptive statistics of diastolic blood pressure in supine posture|
Click here to view
|Figure 4: The descriptive of systolic blood pressure inSBP Sitting position|
Click here to view
|Figure 5: Descriptive statistics of systolic blood pressure in standing position|
Click here to view
|Figure 6: The descriptive analysis of diastolic blood pressure in standing position|
Click here to view
| Discussion on results|| |
The result of the study revealed that, a combination of Brahmyadi compound and Shilajatu Vati has a definite role in lowering BP, which also showed statistically highly significant results with P < 0.001.
The symptoms such as headache, insomnia, and giddiness were reduced after the intervention, while, other symptoms namely fatigue, chest pain, and palpitation showed no much response.
After observing the mean BP values, it is seen that SBP reduced up to 10 mm Hg while DBP reduced up to 6 mm Hg on 7 th day. On 14 th day, SBP reduced up to 14 mm Hg and DBP reduced upto10 mm Hg. On 21 st day, SBP reduced up to 19 mm Hg and DBP reduced up to 12 mm Hg. After treatment, SBP reduced 22 mm Hg and DBP reduced 15 mm Hg.
Freshly detected and untreated cases responded well while treated cases of more than 2 years of history showed lesser improvement. The response was encouraging in majority of the patients where stress played an important role.
Sankhapuspi has been mentioned as a Rasayana in Charaka Samhita (Ca. Ci. 1/3), that it provides freedom from fatigue. Sankhapuspi is also a proven hypotensive drug (Chaturvedi et al., 1966) and this study also proved that Sankhapuspi also decreases BP and pulse rate due to its anti-stress effect.
Shankhapushpi (Convolvulus puricaulis) has been successfully used in the management of Chittodvega-Anxiety disorder. 
Shankhapushpi and Brahmi are the Medhya Rasayanas mentioned in Charaka Chikitsa 1 st chapter.  Jyotishmati as Medhaa Prajna Buddhi Vivardhanam (improves cognitive and intellectual ability) is mentioned in Raja Nighantu.
Vacha has been described in Sushrutha Shareera 10 th chapter as Medha Bala Buddhi Vivardhanah (improves intellect ability and strength). Vacha and Jatamansi are mentioned as sanjnasthapaka (to establish consciousness).  Considering the qualities of drugs, here an attempt is made to study the action of the drugs on HTN and is found effective.
| Conclusion|| |
In the present clinical trial, it was observed that there was a marked reduction in the levels of total BP. Symptoms such as headache, insomnia, and giddiness showed marked improvement while not much reduction was observed in other symptoms such as chest pain, fatigue, and palpitation.
Most of the patients in the study were symptomatic on the contrary to general notion that essential HTN is asymptomatic.
The most commonly observed symptoms in them were a headache, insomnia, fatigue, giddiness, respectively. Symptoms such as palpitation, chest pain were observed more in individuals who had chronic HTN and were already treated.
SBP reduced considerably than DBP. In the present trial with Brahmyadi Churna and Shilajatu Vati, reduction in BP was observed markedly with P < 0.000.
A small limitation of the study was that, the taste of the Churna was not palatable which was difficult for the patients to consume. Hence, extract of the same drug can be taken and made into capsule form or Churnas made into tablet form to make it more palatable and tried. Furthermore, controlled clinical trial with long-term follow-up is recommended.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Gupta R. Defining hypertension in the Indian population. Natl Med J India 1997;10:139-43.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-72.
Whelton PK. Epidemiology of hypertension. Lancet 1994;344:101-6.
Pappachan MJ. Increasing prevalence of lifestyle diseases: High time for action. Indian J Med Res 2011;134:143-5.
Carretero OA, Oparil S. Essential hypertension. Part I: Definition and etiology. Circulation 2000;101:329-35.
Parsania S. A clinical study on the role of Jaladhara and Shankhapushpi (Convolvulus pleuricaulis) in the management of Chittodvega (anxiety disorder) Jamnagar: Department of Kayachikitsa, IPGT and RA, Gujarat Ayurveda university; 2001. p. 35-7.
Vaidya Jadavaji Trikamaji Acharya. Charaka Samhita by Agnivesha, Revised by Charaka and Dridhabala with Ayurveda Deepika Commentary of Chakrapanidatta. 5 th
ed. Chikitsa. 1/103. Varanasi: Chaukhamba Surbharathi Prakashan; 2009. p. 42.
Sharma PV. Dravyaguna-vijnana. Vol. 2. Varanasi: Chaukhambha Bharati Academy; 1995. p. 4-17. In Hindi.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8]